Kira Pharmaceuticals is pioneering complement-targeted therapies to treat immune-mediated diseases. The complement system is a complex with an abundance of proteins involved, but it is implicated in a number of autoimmune and inflammatory conditions across hematology, neurology to dermatology. Using their lead identification, optimization and attribute generation, in-vivo confirmation (LOGIC) platform, Kira is leveraging sponsored research agreements with leading complement biology experts to overcome key challenges of developing complements therapeutics. Kira’s pipeline includes their lead asset, KP104, which is entering Phase 2 clinical trials, with nine other assets in the pipeline.

Kira Pharmaceuticals

Founded: 2017
Location: Cambridge, MA
Employee range: 1 - 10
Clinical stage: Clin2
Therapy area: Complement-mediated diseases (ODD)
Drug types: IMM, ONC, NPH
Lead product: KP104
Funding: $53.5M B+ Jan 2021; $28M B; $18M A

Drug notes:

About:

Jobs: